Clinical Trials Logo

Barrett's Esophagus clinical trials

View clinical trials related to Barrett's Esophagus.

Filter by:

NCT ID: NCT02249975 Completed - Barrett's Esophagus Clinical Trials

Efficacy of CryoBalloon Focal Ablation System on Human Esophageal Barrett's Epithelium

Start date: January 2015
Phase: N/A
Study type: Interventional

The purpose of this study is to assess the efficacy and performance of the C2 Focal Cryoablation System in patients with BE.

NCT ID: NCT02230410 Completed - Barrett's Esophagus Clinical Trials

Cryo Balloon for Residual Barrett's Esophagus

Cryoballoon
Start date: August 2014
Phase: N/A
Study type: Interventional

This study is being done to see if treating residual Barrett's Esophagus after previously having undergone Radiofrequency ablation or Endoscopic Mucosal resection can be eliminated with focal cryotherapy.

NCT ID: NCT02210039 Completed - Barrett's Esophagus Clinical Trials

Using Spectrally Encoded Confocal Microscopy (SECM) to Visualise the Esophagus Using an SECM Probe

Start date: June 2014
Phase: N/A
Study type: Interventional

The study is being done to test the feasibility and tolerability of a SECM imaging probe in patients with Barrett's Esophagus (BE). Subjects will undergo SECM probe imaging while they are under conscious sedation. Spiral SECM imaging will be performed continuously over a pre-determined length. Patients will later be asked for their feedback.

NCT ID: NCT02204150 Completed - Clinical trials for Eosinophilic Esophagitis

Study to Image the Esophagus Using the OFDI Capsule

Start date: February 2012
Phase: N/A
Study type: Interventional

The main purpose of this research is to test the feasibility and tolerability of the tethered capsule Optical Frequency Domain Imaging (OFDI)

NCT ID: NCT02198976 Recruiting - Barrett's Esophagus Clinical Trials

Australian Barrett's Cohort With Dysplasia and Early Cancer Study

ABCDE
Start date: April 2014
Phase:
Study type: Observational

The purpose of this study is to collect prospective observational data regarding endoscopic management and outcomes of patients with Barrett's oesophagus (BO) with high grade dysplasia and/or intramucosal carcinoma. To observe the natural history of patients with low grade dysplastic and non dysplastic Barrett's oesophagus

NCT ID: NCT02162758 Terminated - Barrett's Esophagus Clinical Trials

Effect of Dexlansoprazole 60 mg QD and 60 mg BID on Recurrence of Intestinal Metaplasia in Subjects Who Have Achieved Complete Eradication of Barrett's Esophagus With Radiofrequency Ablation

Start date: July 2014
Phase: Phase 4
Study type: Interventional

This study is designed to evaluate the effect of dexlansoprazole QD and BID dosing on the recurrence of intestinal metaplasia (IM) in subjects who achieved complete eradication of Barrett's esophagus (BE) with high-grade dysplasia (HGD) following radiofrequency ablation (RFA).

NCT ID: NCT02149914 Enrolling by invitation - Barrett's Esophagus Clinical Trials

The Changes of Ryodoraku and HRV After PPI Treatment in GERD Patients

Start date: May 2014
Phase: N/A
Study type: Interventional

Gastroesophageal reflux disease(GERD) mainly related to the reflux of stomach content induced by the dysfunction of lower esophageal sphincter. Proton pump inhibitors (PPI) can effectively block gastric acid secretion but the drug reactions and the degree of improvement in symptoms are sometimes unpredictable. The aim of this study is to investigate the association between the clinical efficacy of PPI in patients with GERD and the personal physical status by Ryodoraku and ANSWatch.

NCT ID: NCT02106910 Completed - Barrett's Esophagus Clinical Trials

Non-Endoscopic Surveillance for Barrett's Esophagus Following Ablative Therapy

Start date: October 27, 2014
Phase: N/A
Study type: Interventional

Subjects presenting to University of North Carolina at Chapel Hill (UNC) Hospitals for routine endoscopic surveillance examinations for current Barrett's Esophagus (BE) or after successful radiofrequency ablation (RFA) of dysplastic Barrett's Esophagus (BE) will be offered enrollment in the study. After informed consent, and the same day as the endoscopic procedure, the subject will undergo administration of the Cytosponge assay. The patient will then undergo routine endoscopic surveillance, using a standard Seattle biopsy surveillance protocol. The Cytosponge will be placed in fixative and shipped to the Fitzgerald laboratory at the University of Cambridge for processing according to their established protocols. Tissue biopsies will undergo standard processing and Hematoxylin and Eosin (H&E) staining, with assessment by expert gastrointestinal pathologists at UNC. The primary outcome variables will be sensitivity and specificity of the novel assay, compared against the gold standard of the presence of recurrent BE as detected by upper endoscopy with biopsies. Secondary outcomes include acceptability of the nonendoscopic assay to the patient (assessed by a standardized tool, the Impact of Events Scale, as well as a visual analogue scale), and likelihood of assay positivity as a function of amount of residual disease (as measured by Prague criteria).

NCT ID: NCT02075905 Completed - Barrett's Esophagus Clinical Trials

Stratifying Risk in Barrett's Esophagus: A Pilot Study for Biomarker-based Patient Management

Start date: March 2014
Phase: N/A
Study type: Observational

Subjects enrolled in this study will have biopsies obtained and sent to Dr. Fitzgerald's lab for analysis of a validated biomarker panel. Subjects will be stratified to either high or low risk of progression to esophageal adenocarcinoma (EAC) based on biomarker panel results. Biomarker panel results will not be communicated to sites. Subjects with low grade dysplasia will be offered the option of treatment (radiofrequency ablation (RFA)) as part of routine care. Subjects with low grade dysplasia who do not want RFA and subjects with no dysplasia will receive surveillance endoscopy in 1 year per routine care. All subjects will be administered a questionnaire seeking information about hypothetical willingness to be randomized to treatment or surveillance.

NCT ID: NCT02066701 Completed - Barrett's Esophagus Clinical Trials

Gene Methylation in the Diagnosis of Barrett's Esophagus: Identification of Candidate Diagnostic Markers

Start date: May 2012
Phase: N/A
Study type: Observational

This study is to identify potential markers from esophageal biopsies and brush cytology for feasibility of use in stool specimens for detection of Barretts Esophagus.